Grant Curry

Grant Curry is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2024, Mr. Curry was most recently a Managing Director at Dyalco, specializing in mergers & acquisitions and activism defense. He has advised on a wide range of biopharma and health care transactions, including Bristol-Myers Squibb in its acquisition of Celgene, Bristol-Myers Squibb in its acquisition of MyoKardia, Novartis on its spin-off of Sandoz, Novartis in its acquisition of AveXis, Novartis in the divestment of its consumer healthcare joint venture interest to GSK, Amgen in its acquisition of Otezla, and Charles River Laboratories in its acquisition of Cognate. Prior to joining Dyalco in 2016 as one of its first employees, Grant was a member of the Global Healthcare Group of UBS.

Mr. Curry earned a B.A. from Whitman College and an MBA from The University of Chicago Booth School of Business.